Here's What Key Metrics Tell Us About Pfizer (PFE) Q2 Earnings

For the quarter ended June 2025, Pfizer (PFE) reported revenue of $14.65 billion, up 10.3% over the same period last year. EPS came in at $0.78, compared to $0.60 in the year-ago quarter.The reported revenue represents a surprise of +6.35% over the Zacks Consensus Estimate of $13.78 billion. With the consensus EPS estimate being $0.58, the EPS surprise was +34.48%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Pfizer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Revenues- Oncology- Elrexfio- Total International: $50 million versus $34.33 million estimated by three analysts on average.Revenues- Primary Care- Comirnaty- United States: $176 million versus the three-analyst average estimate of $62.19 million.Revenues- Primary Care- Prevnar family- Total International: $523 million versus $536.11 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -0.8% change.Revenues- Primary Care- Prevnar family- United states: $860 million versus the three-analyst average estimate of $826.39 million. The reported number represents a year-over-year change of +3.4%.Revenues- Oncology- Ibrance- Worldwide: $1.05 billion compared to the $1.05 billion average estimate based on three analysts. The reported number represents a change of -7.2% year over year.Revenues- Specialty Care- Xeljanz- Worldwide: $322 million compared to the $219.35 million average estimate based on three analysts. The reported number represents a change of +6.3% year over year.Revenues- Specialty Care- Inflectra- Worldwide: $139 million versus $101.04 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +43.3% change.Revenues- Oncology- Xtandi- Worldwide: $566 million versus $528.19 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +14.3% change.Revenues- Oncology- Inlyta- Worldwide: $243 million versus the three-analyst average estimate of $205.85 million. The reported number represents a year-over-year change of -3.6%.Revenues- Specialty Care- Worldwide: $4.38 billion compared to the $4.19 billion average estimate based on three analysts. The reported number represents a change of +7.2% year over year.Revenues- Primary Care- Worldwide: $5.54 billion versus $5.11 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +11.9% change.Revenues- Primary Care- Prevnar family- Worldwide: $1.38 billion compared to the $1.36 billion average estimate based on three analysts. The reported number represents a change of +1.8% year over year.View all Key Company Metrics for Pfizer here>>>Shares of Pfizer have returned -6.8% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity.Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks